42 completed, 35 recruiting, 17 active not recruiting, 11 terminated. 65 Phase 2, 58 Phase 1, 28 Phase 3, 2 Phase 4.
By phase and status
| Phase | Trials | Status |
|---|
| Phase 2 | 65 | Recruiting 23, Completed 18, Active not recruiting 10, Terminated 10, Not yet recruiting 2, Withdrawn 2 |
| Phase 1 | 58 | Completed 19, Recruiting 18, Terminated 11, Active not recruiting 7, Not yet recruiting 2, Withdrawn 1 |
| Phase 3 | 28 | Completed 14, Recruiting 10, Active not recruiting 4 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow BioNTech SE: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220)
Pumitamig, Carboplatin, Cisplatin - Early-Stage Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | 80 | 2026-11-30 | 2026-10-13 |
A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs
BNT3219 - Advanced Solid Tumors | Phase 1 | Not yet recruiting | 207 | 2026-11-01 | 2026-10-23 |
A Clinical Trial to Test if the Investigational Drug BNT3210 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker Sialyl-Tn
BNT3210 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | 173 | 2026-11-01 | 2026-10-21 |
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)
Obrixtamig, Pumitamig, Carboplatin - Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 55 | 2026-10-01 | 2026-10-13 |
A Study of COVID-19 Vaccine(s) in Children and Adults
BNT162b2 - COVID-19 Vaccines | Phase 3 | Recruiting | 700 | 2026-08-31 | 2026-09-28 |
A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV
BNT168, Placebo - HIV -1 Infection | Phase 1 | Recruiting | 126 | 2026-08-04 | 2026-10-14 |
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
BNT162b2 Vaccine, Tdap Vaccine - COVID-19 Vaccines | Phase 4 | Recruiting | 200 | 2026-07-23 | 2026-08-07 |
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
BNT324, Docetaxel, Prednisone/prednisolone - Metastatic Castration-resistant Prostate Cancer | Phase 3 | Recruiting | 736 | 2026-04-22 | 2026-10-16 |
Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors
BNT3214 - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Recruiting | 533 | 2026-03-30 | 2026-08-13 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
Pumitamig, Ipilimumab, Cabozantinib - Advanced Renal Cell Carcinoma (RCC) | Phase 1 / Phase 2 | Recruiting | 474 | 2026-03-26 | 2026-10-23 |
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Pumitamig, Ipilimumab - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Recruiting | 198 | 2026-03-16 | 2026-10-23 |
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Pumitamig, Durvalumab - Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | 850 | 2026-03-16 | 2026-09-30 |
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Pumitamig, Folfox, Capox - Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2 / Phase 3 | Recruiting | 690 | 2026-03-13 | 2026-09-30 |
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Pumitamig, Pembrolizumab - Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | Recruiting | 750 | 2026-03-12 | 2026-10-23 |
A Randomized Clinical Trial Investigating the Safety, Reactogenicity, and Immunogenicity After Immunization With an mRNA-based Mpox Vaccine Candidate in Africa
BNT166a, Placebo - Mpox (Monkeypox), Smallpox | Phase 2 | Recruiting | 310 | 2026-02-20 | 2026-08-11 |
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
BNT351, Placebo - HIV -1 Infection | Phase 1 | Recruiting | 67 | 2026-02-09 | 2026-09-01 |
A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma
Pumitamig, Bevacizumab, Temozolomide - Recurrent Glioblastoma | Phase 2 | Recruiting | 75 | 2026-01-15 | 2026-10-28 |
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | 990 | 2025-12-31 | 2026-10-23 |
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
BNT162b2 Vaccine, Placebo - COVID-19, SARS-COV-2 Infection | Phase 3 | Completed | 5240 | 2025-12-10 | 2026-10-16 |
A Clinical Trial Testing the Safety of Pumitamig (an Investigational Drug) and How Well it Works When Combined With Chemotherapy for People Who Have Not Been Treated Yet for Pancreatic Cancer
Pumitamig, Nab-paclitaxel, Gemcitabine - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 2 | Recruiting | 105 | 2025-12-04 | 2026-07-28 |
Showing 20 of 111. Sign in to see all of them.
Conditions studied
COVID-19 (29) · Carcinoma, Non-Small-Cell Lung (17) · Coronavirus Infections (14) · Colorectal Neoplasms (8) · Breast Neoplasms (7) · Melanoma (7) · Virus Diseases (7) · Small Cell Lung Carcinoma (6) · Neoplasm Metastasis (5) · Respiratory Tract Infections (5) · Stomach Neoplasms (5) · Influenza, Human (4) · Neoplasms (4) · Pancreatic Neoplasms (4) · RNA Virus Infections (4)
Interventions
BNT162 Vaccine (20) · Carboplatin (11) · pembrolizumab (11) · Paclitaxel (8) · Docetaxel (5) · Gemcitabine (5) · 130-nm albumin-bound paclitaxel (4) · Etoposide (4) · atezolizumab (4) · cemiplimab (4) · Bevacizumab (3) · Cisplatin (3) · Itraconazole (3) · Pemetrexed (3) · COVID-19 Vaccines (2)
Countries
United States (83) · Germany (44) · Spain (43) · United Kingdom (39) · Australia (36) · China (32) · South Korea (23) · Italy (22) · Poland (20) · Turkey (Türkiye) (20) · Belgium (19) · France (18) · Canada (17) · Japan (15) · Taiwan (15)
Top investigators
Lily Hu (3) · Christian Ottensmeier, Prof (1) · H. W. Nijman, MD/PhD (1) · Inhye Ahn, MD (1) · Ioannis Karydis, Dr (1) · Joyce O'Shaughnessy, PHD (1) · Kai He, MD, PhD (1) · Mark Socinski, MD (1)
Results publications
PMID 39197299, PMID 37527039, PMID 38400102, PMID 39066372, PMID 40245769, PMID 42286358, PMID 32728218, PMID 32785213, PMID 33053279, PMID 33301246, PMID 33524990, PMID 34043894, PMID 34525277, PMID 34752019, PMID 34907170, PMID 35131133, PMID 35316227, PMID 35320659, PMID 35472295, PMID 35473709, PMID 35653438, PMID 35688554, PMID 35739094, PMID 35771353, PMID 35792746, PMID 36055877, PMID 36120090, PMID 36125366, PMID 36378074, PMID 36652353, PMID 36791162, PMID 36929216, PMID 37079651, PMID 37164012, PMID 37592303, PMID 37698774, PMID 37860278, PMID 38012751, PMID 38016021, PMID 38366591, PMID 38776391, PMID 39097927, PMID 39762422, PMID 39999538, PMID 40237463, PMID 40347227, PMID 40396505, PMID 40591130, PMID 40966692, PMID 40970572
NIH funding
2023 (16), 2025 (10), 2018 (3), 2017 (2), 2019 (2), 2014 (1)